Biocancell Ltd., of Cambridge, Mass., said it is changing its name to Anchiano Therapeutics and will now trade on the Tel Aviv Stock Exchange under the ticker symbol ANCN (formerly BICL). The company is focused on the discovery and development of therapies to treat cancer. It most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer.